Journal article

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B

Lai Wei, Heiner Wedemeyer, Yun-Fan Liaw, Henry Lik-Yuen Chan, Teerha Piratvisuth, Patrick Marcellin, Jidong Jia, Deming Tan, Wan-Cheng Chow, Maurizia R Brunetto, Moises Diago, Selim Gurel, Viacheslav Morozov, Hua He, Yonghong Zhu, Cynthia Wat, Bernadette Surujbally, Alexander J Thompson

PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2018

Grants

Awarded by China National Science and Technology Major Project for Infectious Diseases Control during the 12th Five-Year Plan Period


Funding Acknowledgements

This study was funded in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Professor Lai Wei had additional funding provided by the China National Science and Technology Major Project for Infectious Diseases Control during the 12th Five-Year Plan Period (2012ZX10002003). The funder provided support in the form of salaries for authors HH, YZ, CW and BS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'Contributions to the manuscript' section. Support for third-party writing assistance for this manuscript, furnished by Blair Jarvis Health Interactions, was provided by Roche Products Ltd, Welwyn, UK. LW has received fees for serving as a speaker, consultant, and advisory board member for AbbVie, Bristol-Myers Squibb (BMS), Gilead, Johnson & Johnson (J&J), and GlaxoSmithKline (GSK) within the last 3 years. Additional funding for the study was provided to LW by the China National Science and Technology Major Project for Infectious Diseases Control during the 12th Five-Year Plan Period. HW has received grant/research support from Abbott, BMS, Gilead, Merck, Novartis, Roche, Roche Diagnostics, and Siemens, and has received consulting fees and has been an advisory board and speakers' bureau member for Abbott, AbbVie, Biolex, BMS, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Foundation, Gilead, IST, J&J/Janssen-Cilag/Janssen TE, Medgenics, Merck/Schering-Plough, Novartis, Novira, Roche, Roche Diagnostics, Siemens, Transgene, and ViiV. Y-FL has served as an advisory board member for Roche. HL-YC has received fees for serving as a speaker and advisory board member for Roche, BMS, Gilead, Novartis, and MSD, and as a speaker for Echosens and GSK, and has received an unrestricted grant for HBV research from Roche. TP has received grant research support from BMS, Roche, MSD, Novartis, Fibrogen, and Bayer, and has been a member of advisory boards or speakers' bureaux for BMS, Roche, MSD, Novartis, and GSK. JJ has received fees for serving as a speaker, consultant, and advisory board member for BMS, MSD, Novartis, and Roche within the last 3 years. MRB has been a member of speakers' bureaux for BMS, Gilead, Roche, and Janssen, and has been a member of advisory boards for AbbVie, Roche, Gilead, and MSD. MD has been a member of speakers' bureaux for Roche, MSD, AbbVie, BMS, Gilead, and Janssen. SG has received fees as a member of advisory boards and speakers' bureaux for Roche, BMS, Gilead, Janssen, and MSD. YZ has been a Genentech/Roche employee and has owned Roche stock and options. HH and CW are employees of Roche and declare stock ownership. BS has received fees for serving as a consultant/contract statistician for Roche, through BStats Solutions Ltd, from March 2013 to the present. AJT has received grant funding from AbbVie, Gilead Sciences, BMS, and Merck, has received consultancy fees from AbbVie, Gilead Sciences, BMS, Roche Diagnostics, Merck, and Spring Bank Pharmaceuticals, and has provided sponsored lectures (national or international) for AbbVie, Roche Diagnostics, Gilead Sciences, BMS, and Merck. The China National Science and Technology Major Project for Infectious Diseases Control during the 12th Five-Year Plan Period provided support in the form of salaries to HH, YZ, CW, and BS.